Edoxaban

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Edoxaban and local guidelines before prescribing.

Direct factor Xa inhibitor (DOAC)

Mechanism

Direct factor Xa inhibitor.

Uses

Stroke prevention in non-valvular AF, treatment and prevention of VTE.

Dosing

Side effects

Bleeding, anaemia, rash, abnormal LFT.

Interactions

P-gp inhibitors raise levels; avoid with other anticoagulants.

Contraindications and cautions

Active bleeding, mechanical valve, severe liver disease

Monitoring

Renal function, Hb, weight

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Reduce dose if CrCl 15–50

Overdose and reversal

Andexanet alfa or prothrombin complex concentrate

Special advice

Dose reduce by weight, renal function and interacting drugs; reduced efficacy with CrCl above 95 in AF.

More from the textbook: uses, cautions and other points
Where it is discussed in the book